Breaking News

Abzena Launches AbZelect Platforms for Cell Line Development

Aims to enable rapid generation and selection of high-yielding mammalian CHO cell lines for therapeutic protein and recombinant vaccine production.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Abzena, a CDMO for biologics and bioconjugates, has launched AbZelect and AbZelectPRO cell line development (CLD) platforms for the generation of production cell lines for manufacture of antibodies and recombinant proteins.    AbZelect and AbZelectPRO platforms are designed to enable the rapid generation and selection of high-yielding mammalian CHO cell lines for therapeutic protein and recombinant vaccine production. Designed for traditional protein programs, such as antibodies, AbZelect is o...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters